Arcus Biosciences (NYSE: RCUS) reported Q3 EPS of ($1.00), $0.02 better than the analyst estimate of ($1.02). Revenue for the quarter came in at $48 million versus the consensus estimate of $38.95 million.

For earnings history and earnings-related data on Arcus Biosciences (RCUS) click here.